Chinese Antihypertensive Drug To Go International
This article was originally published in PharmAsia News
Executive Summary
Beijing Second Pharmaceutical started bioequivalence trials on its amlodipine benzenesulfonate tablets in the U.S. last December, a significant step toward procuring current good manufacturing practices audit and registration in the market. Amlodipine benzenesulfonate constitutes the top-ranking antihypertensive drug in China and the world, with Beijing Second Pharmaceutical enjoying the biggest local market share in annual sales. The company's product is expected to obtain FDA's abbreviated new drug application approval in 2009, making it the first-ever China-produced amlodipine export to the U.S. (Click here for more)
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.